NO20091618L - Bicykliske triazoler som proteinkinasemodulatorer - Google Patents

Bicykliske triazoler som proteinkinasemodulatorer

Info

Publication number
NO20091618L
NO20091618L NO20091618A NO20091618A NO20091618L NO 20091618 L NO20091618 L NO 20091618L NO 20091618 A NO20091618 A NO 20091618A NO 20091618 A NO20091618 A NO 20091618A NO 20091618 L NO20091618 L NO 20091618L
Authority
NO
Norway
Prior art keywords
protein kinase
kinase modulators
bicyclic
bicyclic triazoles
triazoles
Prior art date
Application number
NO20091618A
Other languages
English (en)
Norwegian (no)
Inventor
Pierre-Yves Bounaud
Christopher Ronald Smith
Elizabeth Anne Jefferson
Original Assignee
Sgx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgx Pharmaceuticals Inc filed Critical Sgx Pharmaceuticals Inc
Publication of NO20091618L publication Critical patent/NO20091618L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20091618A 2006-10-23 2009-04-23 Bicykliske triazoler som proteinkinasemodulatorer NO20091618L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86255206P 2006-10-23 2006-10-23
US87030906P 2006-12-15 2006-12-15
US91376607P 2007-04-24 2007-04-24
US95284007P 2007-07-30 2007-07-30
PCT/US2007/081841 WO2008051808A2 (fr) 2006-10-23 2007-10-18 Triazoles bicycliques en tant que modulateurs de protéine kinase

Publications (1)

Publication Number Publication Date
NO20091618L true NO20091618L (no) 2009-05-22

Family

ID=38956385

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091618A NO20091618L (no) 2006-10-23 2009-04-23 Bicykliske triazoler som proteinkinasemodulatorer

Country Status (25)

Country Link
US (1) US8507489B2 (fr)
EP (1) EP2084162B1 (fr)
JP (1) JP5378222B2 (fr)
KR (1) KR20090071612A (fr)
AR (1) AR063520A1 (fr)
AU (1) AU2007309149C1 (fr)
BR (1) BRPI0717320A2 (fr)
CA (1) CA2667428A1 (fr)
CO (1) CO6190620A2 (fr)
CR (1) CR10803A (fr)
DK (1) DK2084162T3 (fr)
EA (1) EA200970403A1 (fr)
ES (1) ES2393130T3 (fr)
IL (1) IL197958A0 (fr)
MA (1) MA30871B1 (fr)
MX (1) MX2009004059A (fr)
NO (1) NO20091618L (fr)
NZ (1) NZ575336A (fr)
PE (1) PE20080893A1 (fr)
PL (1) PL2084162T3 (fr)
PT (1) PT2084162E (fr)
SV (1) SV2009003235A (fr)
TN (1) TN2009000142A1 (fr)
TW (1) TW200835492A (fr)
WO (1) WO2008051808A2 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EP2165710A1 (fr) * 2008-09-19 2010-03-24 Institut Curie Récepteur TYRO3 de la tyrosine kinase en tant que cible thérapeutique dans le traitement d'une tumeur de la vessie
WO2010059771A1 (fr) 2008-11-20 2010-05-27 Osi Pharmaceuticals, Inc. Pyrrolo[2,3-b]-pyridines et pyrrolo[2,3-b]-pyrazines substituées
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
RS61281B1 (sr) 2009-12-31 2021-02-26 Hutchison Medipharma Ltd Sintetički intermedijer koristan u pripremi triazolopiridinskih c-met inhibitora
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
WO2011143646A1 (fr) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Inhibiteurs de kinases bicycliques fusionnés
AR085183A1 (es) * 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
UY33549A (es) * 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolil aminas como agentes inhibidores de las quinasas
WO2012042421A1 (fr) 2010-09-29 2012-04-05 Pfizer Inc. Procédé de traitement de la croissance cellulaire anormale
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
CN107141309A (zh) 2011-01-11 2017-09-08 桑诺维恩药品公司 杂芳基化合物及其使用方法
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
CN103459396B (zh) * 2011-02-10 2015-08-19 诺瓦提斯公司 作为c-Met酪氨酸激酶抑制剂的[1,2,4]三唑并[4,3-b]哒嗪化合物
EP2710003A1 (fr) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Inhibiteurs de kinases bicycliques fusionnés
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
CN103958509B (zh) * 2011-09-15 2015-12-23 诺华股份有限公司 作为酪氨酸激酶抑制剂的6-取代的3-(喹啉-6-基硫代)-[1,2,4]三唑并[4,3-a]吡啶化合物
MX2014011987A (es) 2012-04-03 2014-11-10 Novartis Ag Combinaciones de inhibidores de cinasa de tirosina y su uso.
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
WO2014089904A1 (fr) * 2012-12-10 2014-06-19 Abbvie Inc. Composés triazinones
US9364405B2 (en) 2013-03-13 2016-06-14 Avon Products, Inc. Tyrosinase inhibitors
WO2014158943A1 (fr) * 2013-03-13 2014-10-02 Avon Products, Inc Inhibiteurs de tyrosinase
US20150174034A1 (en) 2013-03-13 2015-06-25 Avon Products, Inc. Tyrosinase inhibitors
EP3404032B1 (fr) * 2013-03-13 2025-07-02 F. Hoffmann-La Roche AG Procédé de fabrication de composés de benzoxazépine
WO2014174478A1 (fr) 2013-04-26 2014-10-30 Novartis Ag Combinaisons pharmaceutiques d'un inhibiteur de la pkc et d'un inhibiteur du récepteur tyrosine-kinase c-met
CN105143228B (zh) * 2013-05-10 2017-07-21 江苏豪森药业集团有限公司 [1,2,4]三唑并[4,3‑a]吡啶类衍生物，其制备方法或其在医药上的应用
WO2017049711A1 (fr) 2015-09-24 2017-03-30 上海海聚生物科技有限公司 Dérivé de quinoléine, composition pharmaceutique, méthode de préparation et utilisation de celui-ci

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604091A (en) 1984-03-01 1997-02-18 Microgenics Corporation Methods for protein binding enzyme complementation
JPS60194443A (ja) * 1984-03-16 1985-10-02 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
JPS62228086A (ja) * 1985-12-23 1987-10-06 Takeda Chem Ind Ltd セフエム化合物
EP0228061A3 (fr) 1985-12-23 1988-12-14 Takeda Chemical Industries, Ltd. Composés céphem
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
AU2002251266A1 (en) * 2001-04-10 2002-10-28 Merck Sharp And Dohme Limited Inhibitors of akt activity
WO2002083139A1 (fr) * 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibiteurs de l'activite d'akt
US20030229453A1 (en) 2002-04-09 2003-12-11 Antonysamy Stephen Suresh Crystals and structures of PAK4KD kinase PAK4KD
ATE473980T1 (de) * 2002-12-18 2010-07-15 Vertex Pharma Triazolopyridazine als proteinkinase-inhibitoren
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
BRPI0513899A (pt) * 2004-07-27 2008-05-20 Sgx Pharmaceuticals Inc moduladores de cinase heterocìclica de anel fundido
ATE492544T1 (de) 2004-08-26 2011-01-15 Pfizer Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
CA2590261C (fr) 2004-12-27 2011-08-16 Alcon, Inc. Analogues d'aminopyrazine servant a traiter le glaucome et d'autres maladies et etats medies par rho kinase

Also Published As

Publication number Publication date
AU2007309149A1 (en) 2008-05-02
MA30871B1 (fr) 2009-11-02
KR20090071612A (ko) 2009-07-01
TN2009000142A1 (en) 2010-10-18
CO6190620A2 (es) 2010-08-19
AU2007309149C1 (en) 2013-04-04
ES2393130T3 (es) 2012-12-18
JP2010507578A (ja) 2010-03-11
US8507489B2 (en) 2013-08-13
EP2084162B1 (fr) 2012-09-12
CR10803A (es) 2009-06-16
AU2007309149B2 (en) 2012-09-06
BRPI0717320A2 (pt) 2013-10-22
JP5378222B2 (ja) 2013-12-25
WO2008051808A2 (fr) 2008-05-02
PE20080893A1 (es) 2008-08-26
AR063520A1 (es) 2009-01-28
DK2084162T3 (da) 2012-10-01
EA200970403A1 (ru) 2009-10-30
US20090258855A1 (en) 2009-10-15
PL2084162T3 (pl) 2013-01-31
NZ575336A (en) 2012-04-27
EP2084162A2 (fr) 2009-08-05
CA2667428A1 (fr) 2008-05-02
PT2084162E (pt) 2012-10-09
TW200835492A (en) 2008-09-01
MX2009004059A (es) 2009-04-27
SV2009003235A (es) 2009-10-15
WO2008051808A3 (fr) 2008-07-24
IL197958A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
WO2008051808A3 (fr) Triazoles bicycliques en tant que modulateurs de protéine kinase
MX2009004060A (es) Moduladores de proteina cinasa de triazolpiridazina.
DK1318992T3 (da) Imidazolderivater som Raf-kinaseinhibitorer
NO20071619L (no) Fremgangsmate for fremstilling av indazol forbindelse
NO20070908L (no) Sammensmeltede ringheterocykelkinasemodulatorer
WO2007079164A3 (fr) Inhibiteurs de protéines kinases
MA29935B1 (fr) Inhibiteurs de l'activite de akt
EA200602241A1 (ru) Замещённые индазолы, композиции, содержащие указанные индазолы, способ их получения и применение
MY148468A (en) Compounds and methods for kinase modulation, and indications therefor
MX2009006688A (es) Compuestos y metodos para modulacion de cinasas, e indicaciones para ello.
MA31167B1 (fr) Inhibiteurs de l'activite de akt
NO20091605L (no) Pyridinonforbindelser
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
WO2007109045A8 (fr) composes organiques
NO20084435L (no) C-MET proteinkinaseinhibitorer
ATE469151T1 (de) Pyrrolopyridinderivate als proteinkinaseinhibitoren
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
WO2008033562A3 (fr) Composés inhibiteurs de kinases
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
NO20082476L (no) Bicykliske forbindelser med kinaseinhiberende aktivitet
WO2008002570A3 (fr) Inhibiteurs de la protéine humaine tyrosine phosphatase et leurs procédés d'utilisation
WO2008002569A3 (fr) Inhibiteurs de la protéine humaine tyrosine phosphatase et leurs procédés d'utilisation
EA200870292A1 (ru) Соединения на основе имидазола, композиции, содержащие их, и способы их применения
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application